Dermata Therapeutics Begins Manufacturing for STAR-2 Trial

Dermata Therapeutics ( (DRMA) ) has provided an update.

On May 20, 2025, Dermata Therapeutics announced the initiation of manufacturing for the drug product involved in the XYNGARI™ Phase 3 STAR-2 trial, with the trial expected to start in the fourth quarter of 2025. The company anticipates that the trial results will be available in the first half of 2027, and participants may continue into a 9-month extension study to gather additional data for a potential NDA filing with the FDA in the first half of 2028.

The most recent analyst rating on (DRMA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.

Spark’s Take on DRMA Stock

According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.

Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.

To see Spark’s full report on DRMA stock, click here.

More about Dermata Therapeutics

Dermata Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development of dermatological therapies. The company is known for its innovative approach to treating skin conditions and is actively engaged in clinical trials to bring new treatments to market.

Average Trading Volume: 1,506,440

Technical Sentiment Signal: Sell

Current Market Cap: $5.29M

See more insights into DRMA stock on TipRanks’ Stock Analysis page.